Givaudan H1 Sales Up 6.2% On Like-for-like Basis

Givaudan Group (GVDBF.PK) reported net income of CHF 440 million for the first six months of 2022 compared to CHF 481 million in 2021, resulting in a net profit margin of 12.1% versus 14.3% in 2021. Basic earnings per share were CHF 47.74 versus CHF 52.19 for the same period in 2021.

Sales for the first six months of the year were CHF 3,652 million, an increase of 6.2% on a like-for-like basis and 8.3% in Swiss francs. Last year, the company generated sales of CHF 3,373 million.

Givaudan delivered an operating cash flow of CHF 131 million for the first six months of 2022, compared to CHF 415 million in 2021.

Gilles Andrier, CEO, said, "We are very pleased with our solid performance in the first half of 2022, despite the challenging environment that we are continuing to operate in. I am proud of the way in which we have again demonstrated the resilience of our business and our strong focus on supporting the growth of our customers around the world."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory. Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
Follow RTT